Cargando…
Both intermuscular fat and LVEF decline promote heart failure symptoms in cancer survivors
BACKGROUND: Approximately 20% of cancer survivors treated with chemotherapy experience worsening heart failure (HF) symptoms post-cancer treatment. While research has predominantly investigated the role of cardiotoxic treatments, much less attention has focused on other risk factors, such as adiposi...
Autores principales: | Reding, Kerryn W., O’Connell, Nathaniel S., D’Agostino, Ralph B., Hundley, William, Lucas, Alexander R., Ladd, Amy C., Jordan, Jennifer H., Heiston, Emily M., Ge, Yaorong, Hundley, W. Gregory |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105949/ https://www.ncbi.nlm.nih.gov/pubmed/33964981 http://dx.doi.org/10.1186/s40959-021-00102-1 |
Ejemplares similares
-
Intermuscular Fat Changes Are Related to Reduced Left Ventricular Ejection Fraction During Cancer Therapy (PREVENT-WF-98213)
por: Bellissimo, Moriah P., et al.
Publicado: (2023) -
Increased skeletal intermuscular fat is associated with reduced exercise capacity in cancer survivors: a cross-sectional study
por: Reding, Kerryn W., et al.
Publicado: (2019) -
Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy
por: Jolly, Marie-Pierre, et al.
Publicado: (2017) -
Dispersion of hyperenhancement in late gadolinium enhancement cardiovascular magnetic resonance measured with Moran's I is associated with a decrement in LVEF 6 months after cardiotoxic chemotherapy
por: Jordan, Jennifer H, et al.
Publicado: (2013) -
Atorvastatin Does Not Attenuate Aortic Stiffening After Doxorubicin for Breast Cancer and Lymphoma (PREVENT-WF-98213)
por: Lucas, Alexander R., et al.
Publicado: (2023)